rasagiline

📖 Wiki Page

therapeutic4916 wordssynced 2026-04-02

Rasagiline (Azilect)

...

Rasagiline (Azilect)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">rasagiline</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Current Position</td>
</tr>
<tr>
<td class="label">Regulatory status</td>
<td>Approved for PD (US/EU and other regions)</td>
</tr>
<tr>
<td class="label">Typical dose</td>
<td>1 mg once daily (0.5 mg in selected interactions/comorbidity settings)</td>
</tr>
<tr>
<td class="label">Main evidence strength</td>
<td>Symptomatic PD benefit (monotherapy and adjunct)</td>
</tr>
<tr>
<td class="label">Disease-modification signal</td>
<td>Suggestive but controversial delayed-start signal in ADAGIO</td>
</tr>
<tr>
<td class="label">CBS/PSP evidence</td>
<td>Limited and inconclusive; no robust disease-modifying signal</td>
</tr>
<tr>
<td class="label">Major practical risk</td>
<td>Drug-drug interactions (serotonergic/MAOI/opioid and CYP1A2 context)</td>
</tr>
<tr>
<td class="label">Clinical context</td>
<td>Typical approach</td>
</tr>
<tr>
<td class="label">Early PD monotherapy</td>
<td>1 mg daily</td>
</tr>
<tr>
<td class="label">Adjunct to levodopa with OFF episodes</td>
<td>1 mg daily</td>
</tr>
<tr>
<td class="label">Strong CYP1A2 inhibition present</td>
<td>Consider reduced dose and closer monitoring</td>
</tr>
<tr>
<td class="label">Frailty/polypharmacy</td>
<td>Start low and monitor orthostasis, confusion, sleep effects</td>
</tr>
<tr>
<td class="label">Co-medication class</td>
<td>Risk mechanism</td>
</tr>
<tr>
<td class="label">Non-selective MAO inhibitors</td>
<td>Excess monoaminergic effect</td>
</tr>
<tr>
<td class="label">Meperidine, tramadol, methadone, propoxyphene</td>
<td>Serotonergic/toxic interaction risk</td>
</tr>
<tr>
<td class="label">SSRIs/SNRIs/TCAs</td>
<td>Serotonin toxicity risk (low but non-zero)</td>
</tr>
<tr>
<td class="label">Dextromethorphan</td>
<td>CNS/serotonergic interaction</td>
</tr>
<tr>
<td class="label">Ciprofloxacin and other CYP1A2 inhibitors</td>
<td>Raised rasagiline exposure</td>
</tr>
<tr>
<td class="label">Sympathomimetics</td>
<td>Hypertension/adrenergic effects</td>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score (0-10)</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>7</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>8</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>7</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>5</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>8</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>6</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>8</td>
</tr>
<tr>
<td class="label">Total</td>
<td>60/80</td>
</tr>
</table>

Overview

Rasagiline is an oral, irreversible monoamine oxidase-B ([MAO-B](/proteins/maob-protein)) inhibitor approved for symptomatic treatment of [Parkinson's disease](/diseases/parkinsons-disease). It is used as monotherapy in early disease and as add-on treatment to [levodopa](/therapeutics/levodopa) in patients with motor fluctuations.[@parkinson2002][@olanow2009][@rascol2005][@parkinson2005] In NeuroWiki, rasagiline is relevant for two reasons: (1) established dopaminergic symptomatic benefit in PD, and (2) a broader neuroprotection hypothesis based on its propargylamine scaffold and mitochondrial/anti-apoptotic signaling effects.[@youdim2006][@youdim2008][@weinreb2010]

For [progressive supranuclear palsy](/diseases/psp) (PSP) and [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS), rasagiline should currently be viewed as a low-certainty adjunct for selected symptomatic targets, not a disease-modifying therapy. Evidence in atypical parkinsonism is weaker than in PD and does not show clear progression slowing.[@bensimon2009][@stamelou2017]

Quick Clinical Snapshot

Mechanistic Rationale

MAO-B Inhibition and Dopamine Economy

MAO-B inhibition reduces oxidative dopamine deamination and increases synaptic dopamine availability in striatal pathways.[@youdim2006][@finberg2016] Because rasagiline binds MAO-B irreversibly, pharmacodynamic inhibition outlasts plasma half-life and supports once-daily dosing.[@finberg2016][@us2017] Clinical benefit in PD motor domains is consistent with this mechanism and reproducible across pivotal studies.[@parkinson2002][@rascol2005][@parkinson2005]

Propargylamine Biology Beyond MAO-B

Rasagiline's propargylamine group has been investigated for MAO-B-independent effects: anti-apoptotic signaling, mitochondrial membrane stabilization, and pro-survival transcriptional programs in preclinical models.[@youdim2008][@weinreb2010][@naoi2012] Proposed pathways include BCL-2 family modulation, protein kinase C-linked survival signaling, and attenuation of oxidative injury.[@youdim2008][@weinreb2010][@naoi2012] This mechanistic portfolio is biologically plausible for broad neurodegeneration, but translational certainty remains lower than for dopaminergic symptomatic effects.

Relevance to 4R Tauopathies (CBS/PSP)

CBS and classic PSP are usually 4R tauopathies with network-level degeneration in corticobasal, basal ganglia, and brainstem circuits.[@kovacs2015][@boxer2022] Rasagiline does not directly target [tau](/proteins/tau) aggregation/seed propagation. Any benefit would likely be indirect (mitochondrial stress buffering, oxidative stress attenuation, and limited dopaminergic support for selected motor symptoms), making large disease-modifying effects unlikely as monotherapy.[@bensimon2009][@stamelou2017][@boxer2022]

Pathway Diagram

Mermaid diagram (expand to render)

Clinical Evidence in Parkinson's Disease

Early PD Monotherapy: TEMPO

The TEMPO trial demonstrated improvement in clinical scores for early PD patients treated with rasagiline versus placebo, supporting monotherapy utility in early disease.[@parkinson2002] The study established efficacy and tolerability, and it also seeded the delayed-start disease-modification discussion later explored in ADAGIO.[@parkinson2002][@olanow2009]

Adjunct Therapy in Motor Fluctuations: PRESTO and LARGO

In levodopa-treated patients with wearing-off, PRESTO and LARGO found reduced OFF time and improved functional periods versus placebo, positioning rasagiline as an effective add-on for fluctuation management.[@rascol2005][@parkinson2005] These effects are clinically meaningful for day-to-day function even when disease progression continues.

ADAGIO Delayed-Start Signal and Reanalysis Debate

ADAGIO used a delayed-start design to test potential disease modification. The 1 mg/day arm met all three hierarchical endpoints, while 2 mg/day did not, creating an asymmetric signal that remains debated.[@olanow2009][@olanow2012]

Key interpretations:

Pro-signal interpretation: early sustained separation may indicate biologic effect beyond short-term symptomatic control.[@olanow2009][@olanow2012]
Skeptical interpretation: dose asymmetry and model assumptions permit residual symptomatic confounding.[@olanow2012][@hanagasi2016]

Bottom line: ADAGIO supports a hypothesis of possible modification in a subgroup/dose context, but does not provide definitive proof of progression slowing at population level.[@olanow2012][@hanagasi2016]

Evidence in PSP and CBS

Important Correction: NNIPPS Was Not a Rasagiline Trial

NNIPPS is frequently cited in atypical parkinsonism discussions, but the interventional agent in NNIPPS was riluzole, not rasagiline.[@bensimon2009] Its negative outcome is still relevant as a cautionary benchmark for the difficulty of showing progression modification in PSP/MSA trials, but it cannot be used as direct efficacy evidence against rasagiline.

Rasagiline in PSP: PROSPERA

The PROSPERA randomized clinical trial evaluated rasagiline in PSP and did not show a significant slowing of PSP Rating Scale progression over one year.[@stamelou2017] This is the strongest direct clinical signal currently available for PSP and argues against meaningful monotherapy disease modification.

CBS Extrapolation

Dedicated rasagiline trials in CBS are lacking. Any use in CBS is currently extrapolative from:

pharmacology and PD symptomatic data,
mechanistic plausibility from preclinical neuroprotection,
and limited atypical parkinsonism experience.

Given [tau](/proteins/tau)-centric cortical pathology in CBS, expected effect size is likely modest and symptomatic rather than disease-modifying unless combined with tau-directed interventions.[@kovacs2015][@boxer2022]

Pharmacokinetics, Dosing, and Administration

PK/PD Practicals

Rasagiline is rapidly absorbed, hepatically metabolized (primarily CYP1A2), and exhibits short plasma half-life but prolonged pharmacodynamic impact due to irreversible MAO-B inhibition.[@finberg2016][@us2017][@chen2007] This supports a simple once-daily schedule and facilitates adherence.

Dosing Framework

In CBS/PSP care, dosing is usually conservative and individualized, especially when dysphagia, frailty, orthostatic intolerance, or complex polypharmacy are present.

Drug Interactions and Contraindications

High-Priority Interaction Matrix

Regulatory labeling and pharmacology reviews should anchor prescribing decisions in complex regimens.[@us2017][@chen2007]

Tyramine Question

At approved PD doses, rasagiline remains sufficiently MAO-B selective that strict tyramine-restricted diets are generally not required, but extreme tyramine loads and interacting drugs still warrant caution.[@elsworth1983][@de2006]

Safety and Tolerability

Across PD trials, rasagiline is generally well tolerated. Common adverse effects include headache, arthralgia, dyspepsia, and insomnia; when combined with levodopa, dyskinesia and orthostatic symptoms are more clinically relevant.[@parkinson2002][@rascol2005][@parkinson2005][@chen2007] Neuropsychiatric monitoring remains important in older adults with cognitive vulnerability.

For CBS/PSP populations:

Falls risk, orthostatic hypotension, and executive dysfunction can magnify medication harms.
Benefit-risk should be reassessed frequently, especially after dose changes or added serotonergic/analgesic drugs.

Rubric Scoring (CBS/PSP-Oriented 8-Dimension Framework)

Practical Positioning for CBS/PSP Programs

Rasagiline can be considered a second-line adjunct when clinicians are targeting parkinsonian slowness/rigidity and want a relatively simple oral option, but expectations should be calibrated:

likely symptomatic assistance in a subset,
low confidence for disease-course modification,
strong need for interaction-aware prescribing.

A rational future strategy is combination development: rasagiline for dopaminergic/mitochondrial stress support plus direct tau-pathway agents, rehabilitation, and fall-prevention care bundles.[@stamelou2017][@kovacs2015][@boxer2022]

Research Priorities

Biomarker-stratified atypical parkinsonism trials (tau PET, fluid phospho-tau signatures) to identify potential responder subgroups.

Combination protocols pairing rasagiline with tau-directed therapeutics or anti-neuroinflammatory interventions.

Pragmatic geriatric safety studies in high-frailty PSP/CBS cohorts focused on falls, delirium, and polypharmacy outcomes.

Mechanistic translational studies linking propargylamine signaling to human-relevant tauopathy cellular models.

ADAGIO Endpoint Anatomy (Why Interpretation Remains Controversial)

ADAGIO was designed around a three-endpoint delayed-start framework intended to reduce false attribution of pure symptomatic effects to disease modification.[@olanow2009][@olanow2012] In simplified terms, a disease-modifying interpretation needs all three conditions:

early-start should decline more slowly in stage 1 than placebo,
early-start should maintain superiority at final evaluation,
and delayed-start should not fully catch up after switching to active drug.

The 1 mg/day arm satisfied this structure, but the 2 mg/day arm did not.[@olanow2009] This internal discordance drives most of the controversy. Methodologic critiques emphasize:

nonlinear progression in early PD can distort slope-based inferences,
baseline heterogeneity can create persistent separation without true biologic modification,
and symptomatic carryover may persist longer than assumed in delayed-start statistical models.[@olanow2012][@hanagasi2016]

Supportive arguments still exist:

dose-response in neuropharmacology is not always monotonic in vivo,
subgroup heterogeneity (phenotype, progression velocity, biology) can produce apparent inversion,
and preclinical pro-survival biology is mechanistically coherent with a partial-modification signal.[@youdim2008][@weinreb2010][@olanow2012]

For practical decision-making, ADAGIO is best treated as hypothesis-generating for modification and evidence-confirming for symptomatic utility. That distinction matters in CBS/PSP, where clinicians should avoid overpromising progression effects based on PD delayed-start evidence alone.[@stamelou2017][@boxer2022]

Medicinal Chemistry and Structure-Activity Notes

Rasagiline and [selegiline](/therapeutics/selegiline) are both propargylamine MAO-B inhibitors, but they differ in metabolic liabilities and tolerability framing. Selegiline generates amphetamine-like metabolites, while rasagiline's principal metabolite is 1-aminoindan, which avoids stimulant-like metabolite concerns in routine use.[@youdim2008][@weinreb2010][@chen2007]

Mechanistic implications for translational neurology:

irreversible MAO-B inhibition provides sustained enzyme blockade despite short plasma residence,
propargylamine chemistry supports a broader stress-response signaling hypothesis,
and metabolite profile may influence sleep, anxiety, and autonomic side-effect patterns in real-world polypharmacy contexts.[@finberg2016][@chen2007]

From a CBS/PSP perspective, medicinal chemistry does not solve the central challenge: tau network degeneration is not primarily a dopamine-depletion syndrome. The drug may still offer localized symptomatic benefit in parkinsonian domains and possibly modest stress-buffering effects, but mechanistic distance from tau seeding/spread remains a major biological limitation.[@kovacs2015][@boxer2022]

Practical Drug-Interaction Operations in Complex Clinics

In tertiary movement-disorder clinics, interaction failures are more often process errors than pharmacology ignorance. A practical rasagiline safety workflow:

Reconcile all serotonergic, opioid, cough/cold, and herbal products before initiation.

Flag CYP1A2 inhibitors (for example, fluoroquinolones) and heavy smoking status changes that may alter exposure.

Define a documented escalation plan for agitation, clonus, diaphoresis, fever, or abrupt blood pressure changes.

Re-run medication reconciliation at every care-transition event (hospital discharge, rehabilitation transfer, new psychiatry consult).

This operational framing is especially important in PSP/CBS care where patients frequently cross neurology, geriatrics, palliative medicine, and rehabilitation interfaces. Small coordination failures can produce outsized adverse outcomes in frail patients with dysphagia, falls, and executive impairment.[@us2017][@boxer2022][@chen2007]

Serotonergic Co-prescription: Risk Framing

Absolute prohibitions and real-world practice are not identical. Many clinics co-prescribe selective serotonergic antidepressants with rasagiline when psychiatric burden is clinically important, but only under structured monitoring. Core safeguards include:

lowest effective antidepressant dosing,
explicit symptom checklists for serotonin toxicity,
and pre-defined stop rules for suspect adverse syndromes.

This is risk-managed co-prescribing, not evidence of zero interaction risk. Label guidance still carries high-importance warnings and should anchor local protocols.[@us2017][@chen2007]

CBS/PSP Implementation Guidance (Evidence-Constrained)

Where Rasagiline May Be Reasonable

Mixed syndromes with clear parkinsonian slowness/rigidity where levodopa alone is insufficient or poorly tolerated.
Patients needing very simple oral regimens (once-daily dosing) because treatment complexity is already high.
Cases where clinicians are intentionally trialing low-burden symptomatic adjuncts while planning higher-leverage interventions (rehabilitation, fall prevention, communication support, dysphagia management).

Where It Is Less Likely To Help

Dominant axial instability, severe early falls, marked vertical gaze palsy, or profound cortical dysfunction where dopaminergic leverage is minimal.
Advanced disease stages with severe network-level impairment and high non-motor burden.
Settings with uncontrolled polypharmacy risk where interaction management is unreliable.

Trial-of-Therapy Checklist

Before trial:

Define a narrow symptom target (for example, morning bradykinesia transfer time, not \"overall disease control\").
Document baseline functional metrics and caregiver-observed outcomes.
Confirm interaction screen and orthostatic blood pressure baseline.

During trial (4-8 weeks):

Reassess target symptom with the same instrument/time window.
Monitor orthostasis, confusion, hallucinations, sleep fragmentation, and falls.
Adjust concomitant dopaminergic therapy if dyskinesia or behavioral activation appears.

Stop criteria:

no measurable target improvement,
emergent adverse-risk profile,
or progression trajectory indicating no realistic symptomatic contribution.

This approach keeps rasagiline in an evidence-consistent lane: a bounded symptomatic trial rather than presumed neuroprotection in tauopathy.[@stamelou2017][@boxer2022]

Comparative Positioning Against Other MAO-B Strategies

Rasagiline's strongest comparative advantages are once-daily simplicity, broad clinician familiarity, and a large PD evidence footprint. Comparative limitations include lack of compelling disease-modification proof and weak evidence in atypical parkinsonism populations.[@olanow2009][@stamelou2017][@olanow2012]

Against selegiline:

rasagiline generally has cleaner metabolite framing,
similarly strong symptomatic class effects in PD domains,
and a more extensive disease-modification debate centered on ADAGIO.[@youdim2008][@weinreb2010][@chen2007]

Against newer add-on paradigms:

benefits are usually incremental, not transformative,
interaction management remains central,
and selection is often driven by individual tolerability and care-path complexity rather than large efficacy differentials.

For NeuroWiki treatment ranking purposes, rasagiline remains a moderate-evidence intervention with high actionability in PD symptom management and low confidence for modifying CBS/PSP progression.

Special Populations and Monitoring Nuance

Older Adults With Cognitive Vulnerability

In patients with executive dysfunction, fluctuating attention, or early hallucinosis risk, medication changes should be slower than in trial populations. Rasagiline itself is often tolerated, but cumulative neuropsychiatric burden usually reflects the whole regimen (dopamine agonists, anticholinergics, sedatives, antidepressants), not a single drug in isolation.[@us2017][@chen2007] For CBS/PSP clinics, the practical question is frequently whether rasagiline adds enough functional value to justify one more agent in a fragile stack.

Dysautonomia and Falls

Orthostatic symptoms are common in advanced parkinsonian disorders and can worsen with multidrug regimens. Rasagiline is not a dominant driver of hypotension in most cases, but adding it to levodopa or antihypertensive-heavy regimens can shift balance in susceptible patients. Structured standing blood pressure checks and falls surveillance are therefore more useful than relying on symptom self-report alone.[@rascol2005][@parkinson2005][@boxer2022]

Hepatic and Polypharmacy Context

Because rasagiline is hepatically metabolized with CYP1A2 relevance, periodic medication review is not optional in long-term care. Exposure can change after seemingly unrelated prescribing decisions (for example antimicrobial changes), smoking cessation, or acute hospitalization. A medication "time-out" at each transition point reduces preventable adverse events in real-world care pathways.[@us2017][@chen2007]

Counseling Points for Patients and Caregivers

Clarify that rasagiline is primarily a symptom-management tool in most settings; progression-slowing claims are uncertain outside selected PD interpretations.[@olanow2009][@olanow2012]
Teach red-flag symptoms that need urgent contact: escalating confusion, severe autonomic changes, fever with agitation, or sudden mobility decline after medication changes.
Encourage caregivers to track one or two functional targets (for example transfer time, meal-time motor control, freezing episodes) rather than broad subjective impressions.
Revisit goals every 1-3 months in PSP/CBS, where rapid phenotype shifts may outpace medication benefit.

Expanded Clinical Evidence Synthesis

Additional Randomized and Regional Trials

Beyond TEMPO/PRESTO/LARGO/ADAGIO, several randomized datasets improve confidence in rasagiline's symptomatic class effect across treatment contexts. A placebo-controlled adjunct trial in patients already receiving dopamine agonists showed additional motor benefit, supporting use before levodopa-intensification in selected patients.[@barone2014] Regional phase 3 studies in Japan and China reproduced efficacy and acceptable tolerability in early or fluctuating PD populations, improving external validity across prescribing environments.[@hattori2019][@zhang2018]

These trials are clinically important for two reasons. First, they reduce overreliance on a single delayed-start narrative by showing consistent symptomatic improvement across multiple designs and geographies. Second, they better approximate real-world sequencing, where rasagiline is often introduced at transition points between monotherapy and combination regimens rather than as an isolated first-line decision.

Meta-Analytic Signal for Symptomatic Efficacy

Multiple meta-analyses report modest but consistent motor benefit versus placebo in early PD and as adjunct therapy, with acceptable discontinuation and adverse-event profiles in most cohorts.[@abbruzzese2013][@liu2017][@ma2022][@khan2024] This convergent evidence supports rasagiline as an evidence-based symptomatic option in PD care pathways, especially when clinicians prioritize once-daily administration and low regimen complexity.

At the same time, pooled analyses do not resolve the central disease-modification controversy because they aggregate predominantly symptomatic endpoints, and delayed-start inferences remain design-sensitive. For NeuroWiki ranking, the strongest defensible statement remains: symptomatic efficacy is replicated; neuroprotective/disease-modifying efficacy is not definitively established at population level.

Long-Term Follow-up and Real-World Durability

Long-term observational analyses suggest rasagiline can remain clinically useful over extended treatment horizons, but interpretation is constrained by confounding from background regimen changes and survivor bias.[@rascol2016] In practical terms, this supports periodic reassessment rather than indefinite continuation by inertia. If functional targets are no longer met, deprescribing or strategy pivoting is appropriate.

Preclinical and Translational Biology Deep Dive

Propargylamine Mechanistic Lineage

Earlier medicinal chemistry and pharmacology work established rasagiline as a potent, selective MAO-B inhibitor with durable target engagement.[@youdim1998][@youdim2001] Primate work showed that selective MAO-B inhibition can amplify striatal dopamine production from levodopa, aligning with the clinical add-on rationale in fluctuating PD.[@baram1998]

Neuroprotection Models: Promise and Boundaries

In toxin and proteostasis injury models, rasagiline and related compounds demonstrated neuronal preservation signals, including attenuation of dopaminergic injury and improved cellular stress resilience.[@maruyama2005][@soler2008] Additional experiments with the primary metabolite 1-aminoindan reported favorable behavioral, neurochemical, and molecular effects in aging paradigms, supporting the hypothesis that metabolite biology may contribute to non-dopaminergic signaling profiles.[@baram2015]

Mechanistic studies also implicate glutamatergic modulation and direct interactions with aggregation-relevant proteins as potential adjunctive pathways.[@weinreb2011][@weinreb2015] These findings are biologically interesting and justify continued translational research, but they remain insufficient to infer clinically meaningful progression slowing in human tauopathies without dedicated biomarker-driven trials.

Translational Bridge to CBS/PSP

For CBS/PSP, the preclinical evidence can be interpreted as stress-pathway support rather than direct tau-target engagement. That distinction should guide trial design:

prioritize mechanistically enriched cohorts (oxidative stress or mitochondrial phenotypes),
use biomarker anchors (tau PET, fluid tau markers, neurofilament),
and predefine symptomatic versus progression endpoints to avoid post-hoc over-interpretation.

Pharmacokinetic Variability and Precision Dosing

Population PK and Ethnic Cohort Data

Dedicated pharmacokinetic studies in Japanese, Chinese, and mixed healthy-volunteer cohorts generally show predictable exposure in standard dosing ranges, while highlighting inter-individual variability related to metabolism and transport biology.[@shinotoh2019][@zhou2016][@bellili2022][@bukhari2022][@zhang2020]

Smoking, CYP1A2, and Transporter Genetics

CYP1A2 activity and smoking status can materially shift rasagiline exposure in some cohorts, and transporter polymorphisms may influence PK variability beyond classic metabolic gene effects.[@bellili2022][@bukhari2022] These observations reinforce the need for medication reconciliation and phenotype-aware monitoring at care transitions (hospitalization, smoking cessation, antimicrobial changes).

Practical Precision-Medicine Implications

Routine therapeutic drug monitoring is not standard for rasagiline, but precision-minded practice can still improve safety:

verify smoking status and recent changes,
recheck concomitant CYP1A2 inhibitors/inducers,
adjust dose conservatively in frail patients when exposure risk rises,
and avoid assuming fixed exposure across long-term treatment.

Comparative Effectiveness Versus Selegiline

Head-to-Head and Real-World Data

Comparative studies and real-world analyses suggest broadly similar class-level symptomatic efficacy between rasagiline and selegiline, with differences more often seen in tolerability framing, metabolite considerations, and prescribing persistence rather than large efficacy separation.[@cossu2016][@riederer2017][@cossu2016a][@meco2014]

Clinical service data also indicate distinct utilization patterns and resource profiles across MAO-B choices, likely reflecting clinician preference, patient phenotype, and local formulary constraints as much as pharmacology alone.[@cossu2016a]

Interpreting Comparative Data Correctly

Most comparative datasets are retrospective and vulnerable to channeling bias. Therefore:

use comparative findings as contextual guidance, not definitive superiority claims,
align agent choice with patient-specific goals and interaction risks,
and reassess at fixed intervals rather than locking in class choice indefinitely.

Guideline and Evidence-Based Positioning

International evidence-based medicine reviews from the Movement Disorder Society continue to place MAO-B inhibitors, including rasagiline, as validated options for motor symptom management with context-dependent strength across disease stages and symptom clusters.[@fox2018][@armstrong2025] This aligns with an implementation model where rasagiline is one component of multimodal care rather than a stand-alone disease-course intervention.

For CBS/PSP programs specifically, guideline extrapolation should remain conservative because direct trial data are sparse and mostly negative for progression impact in PSP.[@stamelou2017] The practical role is targeted symptomatic support under explicit stop rules.

CBS/PSP-Specific Clinical Algorithm (Operational)

Step 1: Define Treatable Phenotype

Use rasagiline only when the dominant problem includes a plausible dopaminergic-responsive component (bradykinesia/rigidity overlap), not when axial instability, gaze palsy progression, or cortical/apraxic features dominate from baseline.[@stamelou2017][@boxer2022]

Step 2: Safety-First Eligibility Screen

Before initiation, document:

orthostatic blood pressure profile,
full serotonergic/opioid/cough medicine list,
recent smoking status and antibiotic plans,
caregiver capacity for symptom monitoring.

Exclude or defer when interaction control is weak or recent delirium/falls make incremental pharmacologic risk unacceptable.

Step 3: Bounded Trial With Quantified Targets

Run a 4-8 week trial with one or two predefined outcomes:

timed transfer or gait-initiation metric,
caregiver-rated freezing burden,
or morning-on mobility window.

Stop promptly if targets are not met or adverse-risk balance deteriorates.

Step 4: Integrate, Do Not Isolate

If continued, embed rasagiline in a broader bundle:

[physical therapy](/therapeutics/physical-therapy) and fall prevention,
dysphagia and communication interventions,
caregiver education and medication-transition safeguards.

This keeps therapeutic expectations realistic: incremental symptomatic benefit in selected patients, not disease reversal.

Evidence Limits and Confidence Boundaries

Even after substantial literature expansion, several evidence constraints remain central to interpretation. First, most high-certainty rasagiline data come from [Parkinson's disease](/diseases/parkinsons-disease) motor endpoints, not tau-primary syndromes. Second, delayed-start frameworks can generate divergent conclusions depending on model assumptions and subgroup definitions, as illustrated by the persistent ADAGIO 1 mg versus 2 mg asymmetry.[@olanow2009][@olanow2012][@hanagasi2016] Third, real-world comparative analyses versus [selegiline](/therapeutics/selegiline) are informative but largely non-randomized and susceptible to prescription-channeling and confounding by indication.[@cossu2016][@riederer2017][@cossu2016a]

For CBS/PSP clinicians and caregivers, this means confidence should be tiered by question:

High confidence: rasagiline can provide incremental symptomatic improvement in selected PD-like motor phenotypes.
Moderate confidence: rasagiline is operationally usable in multimorbid older adults when interaction screening and monitoring are robust.
Low confidence: rasagiline modifies tau-driven progression in PSP/CBS as monotherapy.[@stamelou2017][@boxer2022]

This confidence framing prevents two recurrent implementation errors:

Overgeneralizing PD evidence to all atypical parkinsonian syndromes.

Dismissing potentially useful symptomatic tools because they are not disease-modifying.

The practical middle path is disciplined therapeutic trials with explicit goals, stop criteria, and integration into non-pharmacologic care bundles. In systems terms, rasagiline should be treated as a controllable lever within a broader care architecture that includes rehabilitation, caregiver training, fall-risk mitigation, swallowing/communication support, and palliative planning when disease stage requires it.[@fox2018][@armstrong2025]

External Links

[Movement Disorder Society](https://www.movementdisorders.org/)
[Parkinson's Foundation](https://www.parkinson.org/)
[Michael J. Fox Foundation](https://www.michaeljfox.org/)
[ClinicalTrials.gov](https://clinicaltrials.gov/)
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Parkinson Study Group, A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study (2002)](https://pubmed.ncbi.nlm.nih.gov/12470183/)

[Olanow CW, Rascol O, Hauser R, et al, A double-blind, delayed-start trial of rasagiline in Parkinson's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19776408/)

[Rascol O, Brooks DJ, Melamed E, et al, Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily) (2005)](https://pubmed.ncbi.nlm.nih.gov/15766996/)

[Parkinson Study Group, A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study (2005)](https://pubmed.ncbi.nlm.nih.gov/15710852/)

[Youdim MBH, Bakhle YS, Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness (2006)](https://pubmed.ncbi.nlm.nih.gov/15140493/)

[Youdim MBH, Amit T, Bar-Am O, Weinreb O, Rasagiline and its propargyl moiety: therapeutic potential in Parkinson's disease and other neurodegenerative disorders (2008)](https://pubmed.ncbi.nlm.nih.gov/18035186/)

[Weinreb O, Amit T, Bar-Am O, Youdim MBH, Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity (2010)](https://pubmed.ncbi.nlm.nih.gov/16675649/)

[Bensimon G, Ludolph A, Agid Y, et al, Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS Study (2009)](https://pubmed.ncbi.nlm.nih.gov/19029129/)

[Stamelou M, de Silva R, Arias-Carrión O, et al, Rasagiline for progressive supranuclear palsy: a randomised, placebo-controlled trial (2017)](https://pubmed.ncbi.nlm.nih.gov/27230855/)

[Finberg JPM, Rabey JM, Inhibitors of MAO-A and MAO-B in psychiatry and neurology (2016)](https://pubmed.ncbi.nlm.nih.gov/19021231/)

U.S. Food and Drug Administration, Azilect (rasagiline) prescribing information (2017)

[Naoi M, Maruyama W, Inaba-Hasegawa K, Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival (2012)](https://pubmed.ncbi.nlm.nih.gov/17884197/)

[Kovacs GG, Invited review: Neuropathology of tauopathies: principles and practice (2015)](https://pubmed.ncbi.nlm.nih.gov/30295967/)

[Boxer AL, Yu J-T, Golbe LI, Litvan I, Lang AE, Höglinger GU, Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches (2022)](https://pubmed.ncbi.nlm.nih.gov/34083433/)

[Olanow CW, Kieburtz K, Schapira AHV, Why have we failed to achieve neuroprotection in Parkinson's disease? (2012)](https://pubmed.ncbi.nlm.nih.gov/22878642/)

[Hanagasi H, Tufekcioglu Z, Emre M, Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies (2016)](https://pubmed.ncbi.nlm.nih.gov/26988747/)

[Chen JJ, Swope DM, Clinical pharmacology of rasagiline: a new MAO-B inhibitor for Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17610307/)

[Elsworth JD, Glover V, Reynolds GP, et al, Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the cheese effect (1983)](https://pubmed.ncbi.nlm.nih.gov/6804562/)

[de Marcaida JA, Schwid SR, White WB, et al, Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline (2006)](https://pubmed.ncbi.nlm.nih.gov/16856145/)

[Barone P, Santangelo G, Morgante L, et al, Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24919813/)

[Hattori N, Tsuboi Y, Yamamoto A, et al, Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan (2019)](https://pubmed.ncbi.nlm.nih.gov/30205936/)

[Zhang Z, Wang J, Zhang X, et al, Adjunct rasagiline to treat Parkinson's disease with motor fluctuations: a randomized, double-blind study in China (2018)](https://pubmed.ncbi.nlm.nih.gov/29988514/)

[Abbruzzese G, Ceravolo R, Mancino M, et al, Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data (2013)](https://pubmed.ncbi.nlm.nih.gov/23735235/)

[Liu S-Y, Wu J-J, Zhao Y, et al, Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis (2017)](https://pubmed.ncbi.nlm.nih.gov/28293967/)

[Ma C, Wang T, Wang Y, et al, Efficacy of rasagiline monotherapy for early Parkinson disease: A systematic review and meta-analysis of randomized controlled trials (2022)](https://pubmed.ncbi.nlm.nih.gov/35546511/)

[Khan S, Ahmed U, Yousaf A, et al, A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38264500/)

[Rascol O, Fitzer-Attas CJ, Hauser R, et al, Long-term effects of rasagiline and the natural history of treated Parkinson's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27431201/)

[Youdim MBH, Gross A, Finberg JPM, (R)-(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B (1998)](https://pubmed.ncbi.nlm.nih.gov/9564630/)

[Youdim MBH, Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline (2001)](https://pubmed.ncbi.nlm.nih.gov/11716151/)

[Bar-Am O, Amit T, Youdim MBH, Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey (1998)](https://pubmed.ncbi.nlm.nih.gov/9564628/)

[Maruyama W, Naoi M, Akao Y, et al, Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? (2005)](https://pubmed.ncbi.nlm.nih.gov/16007239/)

[Soler R, Martin S, García-Ladona FJ, et al, Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration (2008)](https://pubmed.ncbi.nlm.nih.gov/18399960/)

[Bar-Am O, Amit T, Weinreb O, Youdim MBH, Beneficial behavioral, neurochemical and molecular effects of 1-(R)-aminoindan in aged mice (2015)](https://pubmed.ncbi.nlm.nih.gov/26087462/)

[Weinreb O, Amit T, Mandel S, Youdim MBH, Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro (2011)](https://pubmed.ncbi.nlm.nih.gov/21338509/)

[Weinreb O, Amit T, Mandel S, Youdim MBH, Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to α-synuclein (2015)](https://pubmed.ncbi.nlm.nih.gov/25514361/)

[Shinotoh H, Nakanishi T, Asanuma K, et al, Pharmacokinetics and safety of single and multiple doses of rasagiline in healthy Japanese and caucasian subjects (2019)](https://pubmed.ncbi.nlm.nih.gov/30218626/)

[Zhou Y, Yang H, Li X, et al, Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study (2016)](https://pubmed.ncbi.nlm.nih.gov/26951202/)

[Bellili N, Chouchana L, Ait-Hamou N, et al, Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline (2022)](https://pubmed.ncbi.nlm.nih.gov/36297437/)

[Bukhari MH, Khan SA, Mushtaq S, et al, Rasagiline Pharmacokinetics in CYP1A2 Variant Healthy Smokers & Non-smokers in Different Doses (2022)](https://pubmed.ncbi.nlm.nih.gov/35480532/)

[Zhang Y, Wang Y, Fang Y, et al, Pharmacokinetics and Bioequivalence of Rasagiline Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: An Open, Randomized, Single-Dose, Double-Cycle, Two-Sequence, Crossover Trial (2020)](https://pubmed.ncbi.nlm.nih.gov/33364947/)

[Cossu G, Murgia D, Melis M, et al, Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study (2016)](https://pubmed.ncbi.nlm.nih.gov/27438181/)

[Riederer F, Gryglewski G, et al, Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study (2017)](https://pubmed.ncbi.nlm.nih.gov/28550482/)

[Cossu G, Antonelli F, et al, Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline (2016)](https://pubmed.ncbi.nlm.nih.gov/26474874/)

[Meco G, Bonifati V, Vanacore N, Fabrizio E, Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25010617/)

[Fox SH, Katzenschlager R, Lim S-Y, et al, International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29570866/)

[Armstrong MJ, Okun MS, et al, Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review (2025)](https://pubmed.ncbi.nlm.nih.gov/40055961/)

📖 View canonical wiki page →

rasagiline

Rasagiline (Azilect)

Rasagiline (Azilect)

Overview

Quick Clinical Snapshot

Mechanistic Rationale

MAO-B Inhibition and Dopamine Economy

Propargylamine Biology Beyond MAO-B

Relevance to 4R Tauopathies (CBS/PSP)

Pathway Diagram

Clinical Evidence in Parkinson's Disease

Early PD Monotherapy: TEMPO

Adjunct Therapy in Motor Fluctuations: PRESTO and LARGO

ADAGIO Delayed-Start Signal and Reanalysis Debate

Evidence in PSP and CBS

Important Correction: NNIPPS Was Not a Rasagiline Trial

Rasagiline in PSP: PROSPERA

CBS Extrapolation

Pharmacokinetics, Dosing, and Administration

PK/PD Practicals

Dosing Framework

Drug Interactions and Contraindications

High-Priority Interaction Matrix

Tyramine Question

Safety and Tolerability

Rubric Scoring (CBS/PSP-Oriented 8-Dimension Framework)

Practical Positioning for CBS/PSP Programs

Research Priorities

ADAGIO Endpoint Anatomy (Why Interpretation Remains Controversial)

Medicinal Chemistry and Structure-Activity Notes

Practical Drug-Interaction Operations in Complex Clinics

Serotonergic Co-prescription: Risk Framing

CBS/PSP Implementation Guidance (Evidence-Constrained)

Where Rasagiline May Be Reasonable

Where It Is Less Likely To Help

Trial-of-Therapy Checklist

Comparative Positioning Against Other MAO-B Strategies

Special Populations and Monitoring Nuance

Older Adults With Cognitive Vulnerability

Dysautonomia and Falls

Hepatic and Polypharmacy Context

Counseling Points for Patients and Caregivers

Expanded Clinical Evidence Synthesis

Additional Randomized and Regional Trials

Meta-Analytic Signal for Symptomatic Efficacy

Long-Term Follow-up and Real-World Durability

Preclinical and Translational Biology Deep Dive

Propargylamine Mechanistic Lineage

Neuroprotection Models: Promise and Boundaries

Translational Bridge to CBS/PSP

Pharmacokinetic Variability and Precision Dosing

Population PK and Ethnic Cohort Data

Smoking, CYP1A2, and Transporter Genetics

Practical Precision-Medicine Implications

Comparative Effectiveness Versus Selegiline

Head-to-Head and Real-World Data

Interpreting Comparative Data Correctly

Guideline and Evidence-Based Positioning

CBS/PSP-Specific Clinical Algorithm (Operational)

Step 1: Define Treatable Phenotype

Step 2: Safety-First Eligibility Screen

Step 3: Bounded Trial With Quantified Targets

Step 4: Integrate, Do Not Isolate

Evidence Limits and Confidence Boundaries

See Also

External Links

Allen Brain Atlas Resources

References